Cartesian Therapeutics (NASDAQ: RNAC), a clinical-stage biotech company focused on cell therapy for autoimmune diseases, announced its participation in the H.C. Wainwright 3rd Annual BioConnect Investor Conference. The event will take place at NASDAQ on Tuesday, May 20, 2025, at 9:00 a.m. ET. The company's management will participate in a fireside chat, which will be available via live webcast on Cartesian's website. An archived replay will also be accessible for a limited time in the Events section at www.cartesiantherapeutics.com.
Cartesian Therapeutics (NASDAQ: RNAC), un'azienda biotech in fase clinica specializzata in terapie cellulari per malattie autoimmuni, ha annunciato la sua partecipazione alla 3ª Conferenza Annuale BioConnect per Investitori organizzata da H.C. Wainwright. L'evento si terrà presso il NASDAQ martedì 20 maggio 2025 alle 9:00 ET. Il management dell'azienda parteciperà a una conversazione informale, disponibile in diretta streaming sul sito web di Cartesian. Una registrazione dell'evento sarà inoltre accessibile per un tempo limitato nella sezione Eventi su www.cartesiantherapeutics.com.
Cartesian Therapeutics (NASDAQ: RNAC), una empresa biotecnológica en etapa clínica enfocada en terapias celulares para enfermedades autoinmunes, anunció su participación en la 3ª Conferencia Anual BioConnect para Inversionistas de H.C. Wainwright. El evento tendrá lugar en NASDAQ el martes 20 de mayo de 2025 a las 9:00 a.m. ET. La dirección de la empresa participará en una charla informal, que estará disponible en transmisión en vivo en el sitio web de Cartesian. También se podrá acceder a una repetición archivada por tiempo limitado en la sección de Eventos en www.cartesiantherapeutics.com.
Cartesian Therapeutics(NASDAQ: RNAC)는 자가면역 질환을 위한 세포 치료에 중점을 둔 임상 단계의 바이오텍 회사로서 H.C. Wainwright 제3회 연례 BioConnect 투자자 컨퍼런스에 참여한다고 발표했습니다. 이 행사는 2025년 5월 20일 화요일 오전 9시(동부시간)에 NASDAQ에서 열립니다. 회사 경영진은 비공식 대화에 참여하며, 이는 Cartesian 웹사이트에서 라이브 웹캐스트로 시청할 수 있습니다. 또한 이벤트 섹션(www.cartesiantherapeutics.com)에서 일정 기간 동안 다시보기 영상도 제공됩니다.
Cartesian Therapeutics (NASDAQ : RNAC), une société biotechnologique en phase clinique spécialisée dans la thérapie cellulaire pour les maladies auto-immunes, a annoncé sa participation à la 3e conférence annuelle BioConnect Investor organisée par H.C. Wainwright. L'événement se tiendra au NASDAQ le mardi 20 mai 2025 à 9h00 (heure de l'Est). La direction de l'entreprise participera à une discussion informelle, qui sera diffusée en direct sur le site web de Cartesian. Une rediffusion archivéesera également accessible pendant une durée limitée dans la rubrique Événements sur www.cartesiantherapeutics.com.
Cartesian Therapeutics (NASDAQ: RNAC), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf Zelltherapien für Autoimmunerkrankungen spezialisiert hat, gab seine Teilnahme an der 3. jährlichen BioConnect Investorenkonferenz von H.C. Wainwright bekannt. Die Veranstaltung findet am Dienstag, den 20. Mai 2025, um 9:00 Uhr ET am NASDAQ statt. Das Management des Unternehmens wird an einem Fireside-Chat teilnehmen, der live per Webcast auf der Website von Cartesian verfügbar sein wird. Eine archivierte Wiederholung wird zudem für begrenzte Zeit im Bereich Veranstaltungen auf www.cartesiantherapeutics.com zugänglich sein.
Positive
None.
Negative
None.
FREDERICK, Md., May 13, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that its management expects to participate in a fireside chat at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 20, 2025, at 9:00 a.m. ET.
A live webcast of the presentation and fireside chat is expected to be accessible in the Events section of the Company’s website at www.cartesiantherapeutics.com, where an archived replay of the events will also be available for a limited time.
About Cartesian Therapeutics
Cartesian Therapeutics is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a CAR-T entering Phase 3 clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. A Phase 3 trial of Descartes-08 in patients with generalized myasthenia gravis has received written agreement from the FDA under the Special Protocol Assessment process. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA CAR-T currently being evaluated in a Phase 1 trial in patients with multiple myeloma. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X, formerly known as Twitter.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
